Pipeline and key clinical candidates for these companies ... on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover ...
Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...
State of New Jersey Common Pension Fund D increased its stake in shares of QuidelOrtho Co. (NASDAQ:QDEL – Free Report) by ...
Reports Q4 revenue $39.22M, consensus $40.68M. “2024 was a challenging yet transformative year for PacBio (PACB), marked by the successful ...
Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...
Researchers at Jilin University (Changchun, China) developed a highly sensitive, rapid, and accurate method for analyzing ...
QuidelOrtho (NASDAQ:QDEL – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” ...
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...
Ottawa, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The global Immunoassay market is estimated to reach a valuation of USD 34,490 ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback